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Abstract
Purpose: Circulating tumor cells (CTC) are prognostic in
metastatic breast cancer (MBC).We testedwhether EpCAM-based
capture system (CellSearch) is effective in patients with triple-
negative (TN) MBC, and whether CTC apoptosis and clustering
enhances the prognostic role of CTC.
Experimental Design: CTC enumeration and apoptosis were
determined using the CXC CellSearch kit at baseline and days 15
and 29 in blood drawn from TN MBC patients who participated
in a prospective randomized phase II trial of nanoparticle albu-
min-bound paclitaxel (nab-paclitaxel) with or without tigatuzu-
mab. Association between levels of CTC and patient outcomes
was assessed using logistic regression, Kaplan–Meier curves, and
Cox proportional hazards modeling.
Results:Nineteenof 52 (36.5%),14of 52 (26.9%), and13of49
(26.5%) patients whowere evaluable had elevated CTC (5 CTC/
7.5 mL whole blood) at baseline and at days 15 and 29, respec-
tively. Patients with elevated versus not elevated CTC at each time
point had worse progression-free survival (PFS; P¼ 0.005, 0.0003,
0.0002, respectively). The odds of clinical beneﬁt response for
thosewhohadelevatedversus lowCTCatbaselineanddays15and
29were 0.25 (95%CI: 0.08–0.84;P¼ 0.024), 0.19 (95%CI: 0.05–
0.17; P ¼ 0.014), and 0.06 (95% CI: 0.01–0.33; P ¼ 0.001),
respectively. There was no apparent prognostic effect comparing
CTC apoptosis versus non-apoptosis. Presence of CTC cluster at
day 15 and day 29 was associated with shorter PFS.
Conclusions: CTCwere detected using CellSearch assay in app-
roximately one-third of TNMBCpatients. ElevatedCTC at baseline
and days 15 and 29 were prognostic, and reductions in CTC levels
reﬂected response. Clin Cancer Res; 21(12); 2771–9. 2015 AACR.
See related article by Forero-Torres et al., p. 2722
Introduction
Approximately 20% of all breast cancers fail to express either
estrogen or progesterone receptors (ER, PgR) or the HER2 (1).
While chemotherapy is effective for these so-called "triple nega-
tive" breast cancers, no targeted therapies are available for this
subtype. Preclinical studies have demonstrated activity of tigatu-
zumab, a humanized antideath receptor agonist monoclonal
antibody, which triggers apoptosis within basal-like breast cancer
(2). The Translational Breast Cancer Research Consortium
(TBCRC) conducted a randomized phase II trial comparing nano-
particle albumin-bound paclitaxel with or without tigatuzumab
to determine whether the latter has evidence of activity in patients
with triple-negative (TN) metastatic breast cancer (MBC),
reported as a separate companion manuscript (see related article
by Forero-Torres et al. on p. 2722).
Circulating tumor cells (CTC) are prognostic at baseline and
follow-up in patients with MBC (3–5). The CellSearch system
(Janssen Diagnostics, LLC) is based on a capture strategy using
ferromagnetic particles coated with an antibody to epithelial cell
adhesion molecule (anti-EpCAM; refs. 4, 6). Overall, approxi-
mately one-half of patientswithMBChave5CTC/7.5mLwhole
blood (WB), when evaluated using CellSearch, at baseline before
starting a new therapy, whether ﬁrst-line or later in their clinical
course (4, 6). Subset analyses of prior studies have failed to
consistently identify a clinical or biologic subgroup of patients
with MBC for whom CTC, as enumerated by CellSearch, are not
prognostic (3, 4). However, there has been concern regarding the
performance of the CellSearch assay in detecting CTC in patients
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with triple-negative breast cancer, as these cancers tend to fall into
the "basal" intrinsic subtype that appears to express lower levels of
EpCAM than luminal or HER2-positive breast cancers (7).
In addition to enumeration, CTC genotyping and phenotyping
might provide additional clinical and biologic information. In
this regard, early apoptosis, as might be induced by tigatuzumab,
can be detected with the monoclonal antibody M-30, which is
directed against a neoepitope of cytokeratin 18 disclosed by
caspase cleavage (8). We have previously reported detection and
semiquantiﬁcation of apoptotic CTC in patients with MBC using
the CellSearch platform (9, 10).
We investigated whether CTC are elevated in patients with TN
MBC and hypothesized that CTC enumeration, CTC apoptosis,
and CTC clusters might be prognostic, predict response to tiga-
tuzumab, or provide a surrogate indication of response to either
nab-paclitaxel alone or the combination of nab-paclitaxel and
tigatuzumab. Therefore, we studied CTC in patients with TNMBC
who participated in the TBCRC randomized phase II trial (overall
results reported in a related article by Forero-Torres et al. on
p. 2722).
Materials and Methods
Study design and objectives
This studywas a correlative study of an open label, randomized
2:1 phase II trial of nab-paclitaxel, with orwithout tigatuzumab in
patients with measurable TN MBC (overall results reported sep-
arately in the companion manuscript by Forero-Torres et al. on
p. 2722).
The study was approved by the Institutional Review Board
(IRB) of each participating center, and all the enrolled subjects
provided written consent prior to entry. Eligibility was limited to
patients with TN MBC who were either chemotherapy na€ve or
who had progressed on prior chemotherapy. Patients were strat-
iﬁed for randomization by three categories: no prior chemother-
apy for MBC, prior taxane therapy in the metastatic setting, or no
prior taxane therapy in the metastatic setting. Sixty-four patients
were accrued into the clinical trial and 60 patients received at least
one cycle of therapy.
The primary objective of this correlative study was to deter-
mine the feasibility of detecting CTC before initiating therapy
(baseline) and their prognostic role in TN MBC. Secondary
objectives were designed to investigate the prognostic, predic-
tive, and monitoring roles of CTC levels, CTC apoptosis, and
CTC clusters at baseline, day 15, and day 29 after initiation of
therapy.
Patient staging and follow-up
Details of eligibility, accrual, and conduct of the clinical trial are
reported in the companion manuscript (Forero-Torres et al.,
p. 2722). Relevant to this report, before being enrolled into the
study, all patients had measurable disease at baseline, and the
primary endpoint of the trial was response as determined accord-
ing to the Response Evaluation Criteria in Solid Tumor (RECIST
version 1.1). Throughout the manuscript, the term clinical
response refers either to overall response rate (ORR) deﬁned as
complete response (CR) and partial response (PR) or clinical
beneﬁt rate (CBR) deﬁned as stable disease (SD), PR, and CR
disease for > 4 cycles. Assessment of tumor response was per-
formed every two cycles (every 8 weeks).
Blood draw, CTC enumeration, and characterization
Blood draws for CTC enumeration and characterization were
scheduled at baseline, day 15, and ﬁrst follow-up at day 29. At
each time point, approximately 10 mL of WB was collected into
a 10 cc vacutainer tube that contained a cellular ﬁxative (CellSave
Preservative Tubes, Janssen Diagnostics, LLC). Blood specimens
were maintained and shipped at room temperature, and pro-
cessed within a maximum of 96 hours after blood drawing. Once
the samples were received and blinded at the processing labora-
tory, they were resuspended into 7.5 mL aliquots. CTC enumer-
ation and M-30 (apoptosis) determination was performed using
CellSearch CXC kits (Janssen Diagnostics, LLC) as previously
described (9).
Enumeration of CTC was determined after staining with
DAPI (double stranded DNA), and ﬂuoresceinated anti-cyto-
keratin and anti-CD45 antibodies, using criteria previously
described for CellSearch. The fourth "empty" channel of Cell-
Search was used to measure M-30 expression using monoclonal
antibody M-30 (Peviva) conjugated to phycoerythrin (PE). CTC
apoptosis was further determined by visual inspection for
nucleic condensation and/or fragmentation, as well as granular
cytokeratin. As previously reported (9), as a positive control for
the apoptosis marker for each run, cultured human breast
cancer apoptotic MCF-7 cells, were generated by culturing for
7 days in RPMI1640 media and therefore inducing overgrowth
and apoptosis. The supernatant containing ﬂoating and loosely
adherent cells was then ﬁxed in 0.3% paraformaldehyde and
spiked into 7.5 mL human WB from healthy donors, processed
and analyzed with CellSearch. MCF-7 cell line was purchased
through ATCC.
CTC apoptosis was deﬁned as any M-30 staining and/or visual
evidence of apoptosis (Supplementary Table S1). A specimen was
considered to be positive for CTC apoptosis if 25% ormore of the
CTC met these criteria.
CTC clusters were deﬁned as a group of CTC containing
three or more distinct nuclei, and with contiguous cytoplasm
membranes, as previously described (Supplementary Fig. S1;
ref. 11).
CTC enumeration, CTC clusters, and CTC-M-30 were deter-
mined by two reviewers (C. Paoletti and M.C. Mu~niz). CTC
visual apoptosis was determined independently by two
reviewers (C. Paoletti and K. Aung). The results generated by
each operator were then compared, and discordant results
were reconciled by joint readings.
Translational Relevance
Circulating tumor cells (CTC) are associated with worse
prognosis in metastatic breast cancer (MBC) patients. How-
ever, the role of CTC is unclear in triple-negative (TN) breast
cancer due to low expression of epithelial cell adhesion mol-
ecule (EpCAM) compared with other subtypes of breast can-
cers. Using CellSearch, we have demonstrated that CTC are
prognostic in the subgroup of patients with TN breast cancer,
further substantiating the clinical role of monitoring CTC.
Exploratory analyses suggest that evaluation of CTC clusters
may provide further clinical and biologic insights into the
mechanisms of the metastatic process.
Paoletti et al.
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Healthy donors and sample collection
Blood for CTC apoptosis–positive controls was drawn from
healthy volunteers who gave their informed consent approved by
the University of Michigan IRB.
Statistical analysis
As per the convention used by Smerage and colleagues (4), we
designated 3 patient subgroups according to baseline and sub-
sequent CTC level: group A¼ patients with <5 CTC/7.5mLWB at
baseline; groupBday15 (B15) andgroupBday29 (B29)¼patients
with 5 CTC/7.5 mL WB at baseline, which were reduced to <5
CTC/7.5 mL WB at day 15 (B15) or day 29 (B29), respectively;
groupCday 15 (B15) and groupCday29 (C29)¼patientswith5
CTC/7.5mL at baseline, which persisted as5 CTC/7.5mL at day
15 (C15) or day 29 (C29), respectively. The analysis primarily
consisted of comparing group A to groups B and C. CTC enu-
meration was tabulated for all patients and by treatment arm at
baseline, day 15, and day 29. Comparison of the proportion of
those in group A versus groups B and C between treatment arms
was assessed using c2 tests of independence or Fisher's exact tests.
Associations between levels of CTC, CTC apoptosis, and CTC
clusters at baseline, day 15, and day 29 and ORR and CBR were
assessed using c2 or Fisher's exact tests. Odds ratios (OR) were
computed with 95% conﬁdence intervals (CI) and corresponding
P values for ORR and CBR. Associations between level of CTC,
CTC apoptosis, and CTC clusters at baseline, day 15 and day 29
and progression-free survival (PFS) were assessed with Kaplan–
Meier curves and log-rank tests. PFS was deﬁned from the time of
Patients accrued to the main trial (N = 64)
Patients treated for the main trial/eligible for CTC trial (N = 60) 
1 had no blood draw
7 had no BL blood draw: group D (D)
5 had no day 15: 3A; 2B/C
N = 5D
Baseline: CTC collected (N = 52)
DAY 15: CTC collected (N = 52)
DAY 29: CTC collected (N = 49)
Group A (A)
<5 CTC/7.5 mL
N = 33
<5 CTC/7.5 mL
N = 38: 30A; 3D; 5B15
<5 CTC/7.5 mL
N = 36: 29A; 5B29; 2D
≥5 CTC/7.5 mL
N = 13: 1A; 10C29 [9C15+1B/C]; 2D
N = 5: 2D; 2A; 1B/C
N = 8: 3D, 2A; 3C15
≥5 CTC/7.5 mL
N = 14: 12C15; 2D
Group B/C (B/C)
≥5 CTC/7.5 mL
N = 19
59 patients had at least 1 blood draw
4 progressed before initiation of therapy
Figure 1.
REMARK diagram for patient
enrollment and distribution. Group
D, patients with no blood drawn at
baseline (BL); group A, <5 CTC/7.5 mL
WB at baseline; group B/C, 5 CTC/
7.5 mL WB at baseline; B15 and B29,
patients who cleared their CTC from
5 CTC/7.5 mL at baseline (group
B/C) to <5 CTC at day 15(B15) and
29 (B29), respectively; C15 and C29,
patients who maintained 5 CTC/7.5
mL from baseline (group B/C) to
day 15 (C15) and 29 (C29), respectively.
CTC, Triple-Negative Breast Cancer, Apoptosis, Tigatuzumab
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ﬁrst treatment to the time of disease recurrence or the last follow-
up. Patients who had no recurrence were considered as right
censored. For associations at day 29, benchmark analysis was
used for the patients who had not yet progressed by that time and
had CTC information. Hazard ratios (HR), 95% CIs, and the
corresponding P values were computed with Cox proportional
hazards models. No covariates were entered into any of the
models due to the sample size. Multiple comparisons were not
explicitly controlled for due to the small sample size and explor-
atory nature of the analysis.
We report this study according to the REMARK guidelines
(ref. 12; see Fig. 1).
Results
Patient enrollment
Only 60 of the 64 enrolled patients received any treatment. Of
these 60, blood specimens were not drawn in one patient, and
thus 59 patients were enrolled in this correlative study and had at
least one blood draw within the trial (Fig. 1). Overall, demo-
graphic details are provided in a separate report of the main
therapeutic trial results (see related article by Forero-Torres et al.
on p. 2722). However, demographics are brieﬂy outlined as
follows: the median age was 51 (range, 32–72), and 51 (range,
34–75) years, 33% and 32% had no prior chemotherapy in the
metastatic setting, median number of prior therapy regimens was
2 (range, 0–5) and 1 (range, 0–4), in the tigatuzumab/nab-
paclitaxel and nab-paclitaxel arms, respectively.
CTC enumeration
Incidence. Other investigators have suggested that basal-like, TN
breast cancer cells do not express sufﬁcient EpCAM to be captured
and enumerated with anti-EpCAM–based systems, such as Cell-
Search (7). In this trial that speciﬁcally addressed TN MBC, CTC
were drawn in 52, 52, and 49 patients at baseline, day 15, and day
29, respectively. Seven patients did not have a blood draw at
baseline (Fig. 1, groupD).However, theyhadblooddrawnat least
at one other timepoint. At baseline, CTCwere5CTC/7.5mLWB
in 19 (36.5%) patients (Table 1A; Fig. 1). Thus, 63.5% of patients
did not have elevated CTC by the criteria of the study at baseline
(group A), while 36.5% had 5 CTC/7.5 mL (Fig. 1; group B/C).
A cross-sectional analysis at each timepointwas performed. For
each separate time point, all patients who had a blood draw were
included, regardless ofwhether theyhadprior blooddraws. At day
15 and day 29, 14 of 52 (26.9%) and 13 of 49 (26.5%) patients
had elevated (5 CTC/7.5 mL WB), respectively. Note that while
these patient groups overlap considerably, they are not identical,
as 5 patients who had blood draws at baseline did not have them
at day 15, while a separate 5 patients who did not have baseline
specimens, did have them drawn at day 15. Likewise, 5 patients
who had blood drawn at baseline, and 3 patients who did not
have blood drawn at baseline did not have specimens drawn at
day 29. Furthermore, 3 patients who had blood drawn at day 29
and baseline did not have blood drawn at day 15 and 2 patients
who did not have blood drawn at baseline did have blood drawn
at day 29.
The patients that had <5 CTC at baseline (group A) were
scheduled to have further blood draws at day 15 and day 29.
In particular, at baseline, 33 patients had low CTC level (<5
CTC). At day 15, 3 of these patients did not have blood draw.
The remaining 30 patients continued to have low CTC level at
day 15. Two of the three patients that did not have blood
drawn at day 15 had blood drawn at day 29 with low CTC
levels (<5 CTC). Only one patient converted CTC levels
from low (<5 CTC) at baseline to high (5 CTC) at day
29. The rest of the patients who had blood drawn at subse-
quent time points continued to have low CTC level (<5)
throughout (Fig. 1).
For serial analyses for "CTC response," 19 patients had elevated
CTC (groupB/C) at baseline. At day 15, blood specimenswere not
drawn on two patients. Of the remaining 17 patients, CTC levels
declined to <5CTC/7.5mL in 5 (29%) (B15), while CTC remained
Table 1. Incidence of CTC, CTC apoptosis, and CTC clusters
A. Incidence of CTC
CTC/7.5 mL WB  5 CTC /7.5 mL WB by randomized arm
 1  3  5 Nab-paclitaxel Nab-paclitaxel þ tigatuzumab P
Baseline 61.5% (32/52) 50.0% (26/52) 36.5% (19/52) 31.6% (6/19) 39.4% (13/33) 0.57
Day 15 42.3% (22/52) 32.7% (17/52) 26.9%(14/52) 15.8% (3/19) 33.3% (11/33) 0.17
Day 29 38.8% (19/49) 28.6 (14/49) 26.5%(13/49) 22.2% (4/18) 29.0% (9/31) 0.74
B. Incidence of CTC apoptosis and CTC clusters
CTC apoptosisa CTC clustersb
Baseline Day 15 Day 29 Baseline Day 15 Day 29
5/19 (26.3%) 7/14 (50.0%) 8/13 (61.5%) 8/32 (25.0%) 4/22 (18.2%) 7/19 (36.8%)
C. Apoptosis according to single versus clustered CTC at any time during the trial
Single CTC CTC cluster
# of single CTC cells
% single cell positive
for apoptosis # of CTC in the cluster
% CTC cluster with 1 cell
positive for apoptosis
8,393 20% 943 0.4 %
D. Apoptosis according to single versus clustered CTC at baseline, day 15, and day 29
Baseline Day 15 Day 29
Single cell 516/2,678 (19%) 363/1,505 (24%) 795/4,210 (19%)
Cluster 1/161 (0.6%) 0/283 (0%) 3/499 (0.6%)
aOf those 5 CTC/7.5 mL WB.
bOf those with 1 CTC/7.5 mL WB.
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elevated in the other 12 (C15) (Supplementary Fig. S2). At day 29,
blood was not obtained from 4 patients who had elevated CTC at
baseline. Of the remaining 15 patients who had elevated CTC at
baseline andhadablood specimenat day29, 10 (67%) continued
to have elevated CTC (C29; Supplementary Fig. S2). Thus, approx-
imately one-third of patients experienced a "CTC response" to
therapy.
The incidence of elevatedCTC (5CTC/7.5mLWB) at baseline
was similar for patients in the nab-paclitaxel and nab-paclitaxelþ
tigatuzumab arms (31.6% vs. 39.4%, P ¼ 0.57). There was no
signiﬁcant difference in CTC enumeration between the arms at
day 15 or day 29 (Table 1).
Prognosis based on CTC enumeration. In the overall clinical trial,
tigatuzumab had no beneﬁcial effect (see related article by
Forero-Torres et al. on p. 2722). However, 5 patients in the
combination arm had long PFS (11.1, 15.3, 22.4, 26.0, and
34.2 months). All of these patients began the trial with <5 CTC
and their CTC levels remained low through day 15 and 29.
Additionally, there was one patient with long-term PFS in the
control arm (1,004 days) who also maintained <5 CTC
throughout the ﬁrst 29 days. An exploratory analysis failed to
demonstrate any difference in outcomes in the tigatuzumab-
treated patients versus the control group according to baseline
CTC levels (Supplementary Fig. S3). Thus, for the remaining
analyses, all patients were considered regardless of the arm to
which they were assigned.
Numerous reports have demonstrated that CTC, as enumerated
by CellSearch, are prognostic in MBC (3, 4, 6). However, none of
these has prospectively addressed the speciﬁc prognostic role of
CTC in patients with TNMBC. At baseline, patients with elevated
CTC (5 CTC/7.5 mL WB) had a signiﬁcantly worse PFS than
patients with <5 CTC/7.5 mL WB. Median PFS for patients with
elevated vs. not elevatedCTCat baseline¼3.6 vs. 1.9months (P¼
0.005; Fig. 2A).
Likewise, failure to clear CTC by day 15 and by day 29 was also
associated with worse outcomes: median PFS elevated versus not
elevated ¼ 3.6 versus 1.9 months at day 15 and 3.7 versus 1.9
months at day29 (P¼0.0003andP¼0.0002, respectively; Fig. 2B
and 2C). The HRs (95% CIs) for progression for elevated (5
CTC/7.5 mL WB) compared with nonelevated CTC at baseline,
day 15, and day 29 were 2.3 (1.3–4.4; P ¼ 0.007), 3.2 (1.6–6.4;
P ¼ 0.0007), and 3.5 (1.7–7.2; P ¼ 0.0005), respectively
(Fig. 2A–C).
Response rate according to CTC enumeration.Overall, the response
rate in the clinical trial was 26%, and the CBR was 45%, with no
apparent difference in the assigned arms (see related article by
Forero-Torres et al. on p. 2722). We correlated CTC levels with
RECIST ORR and CBR (Fig. 3). Of the 19 patients with5 CTC at
baseline, only 4 (21.1%) had a CR or PR, whereas 12 of the 33
(36.4%) who did not have elevated CTC experienced a response
(P¼ 0.25). Likewise, at days 15 and 29, 3 of 14 (21.4%), and 1 of
13 (7.7%) patients who had elevated CTC had CR or PR, com-
pared with 14 of 38 (36.8%), and 14 of 36 (38.9%) of patients
without elevated CTC who had objective responses (P ¼ 0.34,
0.043, respectively). Although not statistically different, the odds
of overall response for those who had elevated versus low CTC at
baseline and days 15 and 29 were 0.47 (95% CI, 0.13–1.73; P ¼
0.25), 0.47 (95% CI, 0.11–1.97; P ¼ 0.30), and 0.13 (95% CI,
0.02–1.12; P ¼ 0.064).
As most TN MBCs are rapidly growing, one would expect
stable disease to be a function of therapeutic beneﬁt rather than
indolent disease. To increase the power of our exploratory analysis,
we correlated CTC response with CBR (Fig. 3). Of the patients
with elevated CTC at baseline, only 7 of 19 (36.8%) had clinical
beneﬁt, while 23 of 33 (69.7%) who did not have elevated
CTC experienced clinical beneﬁt. Likewise, at day 15, clinical
beneﬁt was observed in 4 of 14 (28.6%) compared with 26 of
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Figure 2.
Progression-free survival (PFS) according to CTC levels (5 CTC/7.5 mL) at
baseline (A), day 15 (B), and day 29 (C). Red line, <5 CTC/7.5 mLwhole blood;
blue line, 5 CTC/7.5 mL whole blood.
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38 (68.4%) patients without elevated CTC. The results at day 29
were similar [clinical beneﬁt¼ 2/13 (15.4%) vs. 27/36 (75.0%) for
elevated vs. non-elevated CTC]. The odds of clinical beneﬁt
response for those who had elevated versus low CTC at baseline
anddays15and29were0.25 (95%CI, 0.08–0.84;P¼0.024), 0.19
(95%CI, 0.05–0.17; P¼ 0.014), and 0.06 (95%CI, 0.01–0.33;P¼
0.001), respectively. These results were statistically signiﬁcant.
Correlation ofCTC responsewith clinical response. For those patients
with elevated CTC at baseline (Supplementary Fig. S2), we have
designated reductionofCTC to<5/7.5mLWBas a "CTC response."
We performed an exploratory analysis to determine whether CTC
response correlatedwithORRandCBR(Supplementary Fig. S4).Of
the 19patients in groupsB/Catbaseline, 5hadadecline to<5CTC/
7.5mlWB (B15), whereas 12 did not (C15; blood was not obtained
at day 15 and 29 in 1 patient and at day 15 for another patient;
Supplementary Fig. S2). The ORR at day 15 in B15 was 40% (2/5
patients) compared with 17% (2/12 patients) in C15 (Supplemen-
tary Fig. S4; P¼ 0.54). CBRwas 80% (4/5 patients) for groupB, but
only 25% (3/12 patients) in group C (P ¼ 0.10). Power was quite
limited to effectively determine whether this difference in response
rates between those in groups B andCwas statistically signiﬁcant or
due to play of chance. However, there was a trend for higher
response rates for those who cleared their CTC by day 15. Similar
results were observed at day 29 (Supplementary Fig. S4).
Taken together, these data regarding CTC and ORR and CBR
suggest that patientswith elevatedCTCat baseline or early follow-
up are less likely to respond to chemotherapy.
CTC apoptosis
Incidence of CTC apoptosis. At baseline, 5 of the 19 (26.3%)
patients who had 5 CTC/7.5 mL WB were considered to be
positive for CTC apoptosis (deﬁned as having 25% of the CTC
positive for apoptosis; Table 1B). At day 15 and 29, 7 of 14
(50.0%) and 8 of 13 (61.5%) patients were considered to have
CTC apoptosis.
Prognostic role of CTC apoptosis.Median PFS was not signiﬁcantly
different for those with or without CTC apoptosis at baseline (1.9
vs. 2.1 months, respectively). Although power was limited, there
was no suggestion that the presence or absence of CTC apoptosis
at any time point predicted PFS (Table 2).
CTC apoptosis and response. The ORR and CBR were explored
according to CTC apoptosis. ORR was 20% (1/5 patients), 14%,
(1/7patients), and13%(1/8patients) at baseline, day 15, andday
29, respectively for patients who had CTC apoptosis compared
with 21% (3/14 patients), 29% (2/7 patients), and 0% (0/5
patients) for those who had CTC but did not meet the criteria
for CTC apoptosis (Table 2 and Supplementary Fig. S5).
Likewise, CBR was 20% (1/5), 29% (2/7), and 13% (1/8) for
patients with CTC apoptosis at baseline, day 15, and day 29,
respectively, compared with 43% (6/14), 29% (2/7), and 20%
(1/5) for patients who had elevated CTC but did not have CTC
apoptosis.
CTC clusters
Incidence of CTC clusters. We hypothesized that CTC in a cluster
might have prognostic implications that differ from a single cell,
even though both are counted only as one CTC by the CellSearch
clinical algorithm. At baseline, 8 (25.0%) of the 32 patients with
any CTC had one or more clusters (Table 1B). Of the 19 patients
who had 5 CTC/7.5 mL WB, 7 (36.8%) had CTC clusters. In
contrast of the 13 patients with 1–4 CTC as per CellSearch criteria,
1 (7.7%) had CTC clusters (P ¼ 0.10).
Prognostic role of CTC clusters. At baseline, median PFS
was around 2.0 months for those with or without CTC clusters
12/33 14/38 14/36
4/19 3/14
1/13
23/33 26/38
27/36
7/19
4/14
2/13
0
10
20
30
40
50
60
70
80
%
 R
EC
IS
T 
re
sp
on
se
P = 0.25
P = 0.02
P = 0.34
P = 0.01
P = 0.043
P < 0.001
CTC/7.5 mL <5 ≥5        <5 ≥5 <5  ≥5     <5  ≥5  <5       ≥5   <5 ≥5
ORR                      CBR    ORR      CBR                ORR   CBR
Time
Type of clinical 
response
Baseline                                          Day 15           Day 29
Figure 3.
Association of CTC level with
response ORR and CBR at baseline,
day 15, and day 29 (clinical response¼
either ORR or CBR, as deﬁned in
Materials and Methods).
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(Table 2). There was no difference in PFS between those who had
presence of CTC clusters at baseline and those who did not, P ¼
0.34. Although there were smaller sample sizes, there was a
signiﬁcant difference in PFS between those with clusters at day
15 andday29 than thosewithout (P¼0.028, 0.009, respectively),
such that those with clusters had worse PFS.
CTC clusters and response. We also performed an exploratory
analysis of ORR and CBR according to CTC clusters. ORR was
13% (1/8), 0% (0/4), and 0% (0/7) for patients who had CTC
clusters comparedwith 21%(5/24), 28% (5/18), and 33% (4/12)
for those who had CTC but did not meet the criteria for CTC
clusters at baseline, day 15 and day 29, respectively (Table 2).
Likewise, CBR was 38% (3/8), 0% (0/4) and 0% (0/7) for
patients with CTC clusters at baseline, day 15, and day 29, respec-
tively, compared with 46% (11/24), 39% (7/18), and 50% (6/12)
for patients who had elevated CTC but did not have CTC clusters.
CTC clusters and apoptosis. A total of 194 CTC clusters, containing
943 CTC, were detected among the 8 patients at any time within
the trial. Only 4 of the cells (0.4%) found in clusters were
apoptotic, as determined either due to M-30 staining and/or
visual evidence of apoptosis (Table 1C). In contrast, 1,674 of
8,393 single CTC (20%) that were identiﬁed in all the patients at
any timewithin the trial were found to be apoptotic (Table 1C). In
particular, CTC apoptosis was 19% (516/2678), 24%, (363/
1505), and 19% (795/4210) at baseline, day 15, and day 29,
respectively for single cells compared with 0.6% (1/161), 0% (0/
283), and 0.6% (3/499) for cells within clusters (Table 1D).
Discussion
In this correlative study to TBCRC study 019, we have con-
ﬁrmed that the performance of a CTC assay system based on anti-
EpCAM immunocapture (CellSearch) is feasible in patients with
TN MBC. Approximately one-third of such patients enrolled in
this clinical trial had5CTC/7.5mLWBat baseline. Furthermore,
baseline elevated CTC were associated with a worse prognosis
(PFS), and failure to reduce CTC to <5/7.5 mLWB by ﬁrst follow-
up was highly suggestive of resistance to chemotherapy, in this
case nab-paclitaxel.
These data are similar to those previously reported for
patients with MBC regardless of biologic, or intrinsic, subtype
(3, 4, 6). In this regard, a recently published pooled analysis of
CTC results from 54 European centers demonstrated that 44%
of 746 patients with TN MBC had 5 CTC/7.5 mL WB (3). Our
prospective study further conﬁrms that the performance char-
acteristics of the CellSearch assay are similar in patients with
triple-negative MBC to those in patients with hormone receptor
or HER2-positive breast cancer. Taken together, although the
sensitivity of CellSearch may be slightly lower in TN versus
non-TN MBC, these data refute the claim of other authors who
have suggested that an EpCAM-based assay might not be
applicable to patients with TN or "basal"-like breast cancers
due to low expression of this marker (7).
Our results are also consistent with those of a prospective,
randomized clinical trial conducted by SWOG (S0500), which
demonstrated that patients who have elevated CTC at baseline
before starting a new, ﬁrst-line chemotherapy for MBC, and
who fail to reduce them to <5/7.5 mL WB by ﬁrst follow-up
(group C), appear to be relatively, if not absolutely, resistant to
the chemotherapy regimen they received. Furthermore, in
S0500, the very short overall survival of patients in group C
(median OS 13 months) suggested that their cancers are more
likely to be resistant to most other types of chemotherapy that
might be applied subsequently (4). In TBCRC 019, all patients
had TN MBC and were stratiﬁed to ﬁrst or later line of che-
motherapy. Therefore, their prognosis is even worse than the
more general population who enrolled in SWOG S0500 or
those in the pooled analysis. Indeed, PFS for those with
elevated CTC at baseline, or at 2 or 4 weeks after starting
therapy, was <2 months. Overall survival was not a measured
endpoint in this trial, and is unavailable.
In addition, the secondary objectives were to determine the
prognostic, predictive, and monitoring roles of CTC levels, CTC
apoptosis, and CTC clusters at baseline, day 15, and day 29 after
initiation of therapy. In particular, we investigated whether CTC
apoptosiswaspredictive of beneﬁt of the additionof the antideath
receptor agent, tigatuzumab. Unfortunately, in the parent trial,
there was no discernable difference in any endpoint between
those who did or did not receive tigatuzumab. Although CTC
levels were prognostic overall, there was no evidence in an
Table 2. Association of CTC enumeration, apoptosis, and clusters with outcomes
Baseline
CTC enumerationa CTC apoptosisb CTC clustersc
ORR P CBR P PFS P ORR P CBR P PFS P ORR P CBR P PFS P
No 12/33 (36.4) 0.25 23/33 (69.7) 0.021 3.6 0.005 3/14 (21.4) 1.0 6/14 (42.9) 0.60 1.9 0.47 5/24 (20.8) 1.0 11/24 (45.8) 1.0 2.3 0.34
Yes 4/19 (21.1) 7/19 (36.8) 1.9 1/5 (20.0) 1/5 (20.0) 2.1 1/8 (12.5) 3/8 (37.5) 2.0
Day 15
CTC enumerationa CTC apoptosisb CTC clustersc
ORR P CBR P PFS P ORR P CBR P PFS P ORR P CBR P PFS P
No 14/38 (36.8) 0.34 26/38 (68.4) 0.010 3.6 0.0003 2/7 (28.6) 1.0 2/7 (28.6) 1.0 1.8 0.11 5/18 (27.8) 0.54 7/18 (38.9) 0.26 2.5 0.028
Yes 3/14 (21.4) 4/14 (28.6) 1.9 1.7 (14.3) 2/7 (28.6) 2.1 0/4 (0) 0/4 (0) 1.8
Day 29
CTC enumerationa CTC apoptosisb CTC clustersc
ORR P CBR P PFS P ORR P CBR P PFS P ORR P CBR P PFS P
No 14/36 (38.9) 0.043 27/36 (75.0) 0.0002 3.7 0.0002 0/5 (0) 1.0 1/5 (20.0) 1.0 1.8 0.73 4/12 (33.3) 0.25 6/12 (50.0) 0.044 2.7 0.009
Yes 1/13 (7.7) 2/13 (15.4) 1.9 1/8 (12.5) 1/8 (12.5) 2.0 0/7 (0) 0/7 (0) 1.8
NOTE: Values in parentheses are numbers expressed in %. PFS is median time to progression in months.
aFor CTC enumeration: No, <5 CTC/7.5 mL; Yes, 5 CTC/7.5 mL.
bFor CTC apoptosis: No, 5 CTC/7.5 mL with <25% apoptotic; Yes, 5 CTC/7.5 mL with 25% apoptotic.
cCTC clusters: No, 1 CTC/7.5 mL with no cluster; Yes, 1 CTC with at least 1 cluster.
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exploratory analysis that patients who either did or did not have
elevated CTC received any beneﬁt from tigatuzumab.
We did not detect a statistically signiﬁcant association between
CTC enumeration and ORR at baseline or day 15. However, the
statistical power to do sowas quite poor due to a very low number
of true responses. Taken together, these data suggest that patients
with elevated CTC at baseline or early follow-up are less likely to
respond to chemotherapy and that CTC response could serve as a
surrogate for clinical response in future phase II trials of new
agents.
There was an association between CTC at baseline and CBR,
but again power was limited to determine if the visual obser-
vation of this association at subsequent time points was sta-
tistically signiﬁcant or due to play of chance. Likewise, there
was a visual, but not statistically signiﬁcant association between
CTC response and clinical response (ORR and CBR) at days 15
and 29.
Taken together, these data suggest that patients with elevated
CTC at baseline or early follow-up are less likely to respond to
chemotherapy and that CTC response could serve as a surrogate
for clinical response in future phase II trials of new agents.
As tigatuzumab appears to function by activation of the death
receptor, we had hypothesized that the early appearance of CTC
apoptosis might serve as an early indication of tigatuzumab
activity. In this study, we failed to show that the presence or
absence of CTC apoptosis at any time point predicted PFS, ORR,
or CBR, either in association with tigatuzumab or overall.
Published data regarding CTC apoptosis are conﬂicting. Hou
and colleagues (13) reported that CTC apoptosis (assigned by
nuclearmorphology) at baseline in patients withmetastatic SCLC
was associated with worse PFS an OS compared with their
absence, a ﬁnding similar to that of Smerage and colleagues
(9) in MBC patients. In contrast, Rossi and colleagues (10) have
suggested that appearance of CTC apoptosis in 8 patients with
MBC was associated with response to chemotherapy. The issue of
CTC apoptosis and therapy response requires further investiga-
tion. The failure to show that the presence or absence of CTC
apoptosis at any time point predicted PFS, ORR, or CBR, either in
association with tigatuzumab or overall in our trial is not sur-
prising, as tigatuzumab was inactive in the overall trial.
CTC clusters have been previously reported in the blood of
patients with lung, renal, prostate cancer, and recently breast
cancer (11, 13–16). In our study, at baseline, 25% of patients of
the 32 patients with 1 CTC/7.5 mL had one or more clusters.
Although there was no difference in PFS between those who had
CTC clusters at baseline and those who did not, we detected a
signiﬁcant difference in PFS between those with residual clusters
at day 15 and day 29 compared with those with CTC but without
clusters. Hou and colleagues have shown that the presence of CTC
clusters was signiﬁcantly associatedwithworse prognosis in SCLC
(13). Likewise, Aceto and colleagues (16) have recently reported
that the presence of CTC clusters isolated by a novel microﬂuidic
device in blood from patients with MBC and prostate cancer was
associated with shorter PFS (16).
Of interest, Hou and colleagues reported that in their study of
CTC in patients with SCLC, no CTC within a cluster exhibited
apoptotic morphology. Although the incidence of CTC clusters in
our population of TN MBC was lower than that observed by
Hou and colleagues in SCLC, we similarly observed few apoptotic
CTC (by M-30 expression and visual inspection) within clusters
(0.4%), whereas single CTC were much more likely to appear
apoptotic (20%). Furthermore, during treatment with nab-pac-
litaxel, although the relative percent of patients with elevated CTC
declined (reﬂecting a CTC response), approximately one-ﬁfth of
the single-cell CTC remained apoptotic, whereas the incidence of
observed apoptosis in CTC clusters remained less than 1%. The
numbers of patients in these categories were too small to perform
meaningful evaluation of outcomes according to these evalua-
tions, but these data suggest that clustering of CTC may confer
relative resistance to cytotoxic drugs.
A strength of this correlative study is that all patients were
prospectively enrolled into a phase II clinical trial with con-
trolled eligibility criteria, prescribed treatments, and high qual-
ity outcomes assessment. However, a weakness of this study is
the small sample size, which limits our CTC-based subgroup
analyses, and the lack of activity of the investigational agent,
tigatuzumab.
In summary, the results of this correlative trial validate that CTC
are indeed elevated and are prognostic in TN MBC patients
receiving chemotherapy. CTC apoptosis needs further investiga-
tion with a larger sample size. In addition, quantiﬁcation of CTC
clusters might add additional prognostic information to simple
CTC enumeration.
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